CN104530009A - Amantadine tetrazolium derivative, and preparing method and application thereof - Google Patents
Amantadine tetrazolium derivative, and preparing method and application thereof Download PDFInfo
- Publication number
- CN104530009A CN104530009A CN201510016493.2A CN201510016493A CN104530009A CN 104530009 A CN104530009 A CN 104530009A CN 201510016493 A CN201510016493 A CN 201510016493A CN 104530009 A CN104530009 A CN 104530009A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- present
- inhibitor
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 5
- 229960003805 amantadine Drugs 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 3
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 claims description 2
- IKNZBNHVVQIRTO-UHFFFAOYSA-N 2h-tetrazole-5-carboxylic acid Chemical compound OC(=O)C=1N=NNN=1 IKNZBNHVVQIRTO-UHFFFAOYSA-N 0.000 claims description 2
- NVDBBGBUTKLRSN-UHFFFAOYSA-N 3-[1-(2-phenoxyethyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CCOC1=CC=CC=C1 NVDBBGBUTKLRSN-UHFFFAOYSA-N 0.000 claims description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 abstract description 2
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000000452 restraining effect Effects 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- -1 Amantadine tetrazole Chemical class 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 108090000631 Trypsin Chemical class 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical class CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000012588 trypsin Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of drugs related to diabetes, in particular to a dipeptidyl peptidase-IV inhibitor with a general formula I, a preparing method of the inhibitor, and an application of the inhibitor to preparation of the diabetes drugs. The inhibitor contains a halogen-substituted amantadine tetrazolium structure. Please see the formula in the specification, wherein R1 is selected from halogen substituent groups.
Description
Technical field
The present invention relates to the pharmaceutical field relevant to diabetes.Specifically, the present invention relates to medicative dipeptidyl peptidase-iv inhibitor containing amantadine tetrazole structure of diabetes and preparation method thereof, containing their pharmaceutical composition and the medicine in treatment diabetes.
Background technology
According to statistics, global diabetic subject nearly about 2.5 hundred million in 2007, wherein large absolutely number is II type (i.e. non-insulin-depending type) diabetic subject.Mainly contain sulfonylurea, N1,N1-Dimethylbiguanide class and trypsin class medicine at the antidiabetic medicine of Clinical practice at present, what go on the market in recent years also has medicament of insulin sensitizer and alpha-glucosidase inhibitor etc.These medicines have good therapeutic action, but the serious side effects such as ubiquity hypoglycemia, and there is safety issue in long-term treatment, as problems such as liver toxicity and body weight increases.
DPP IV (dipeptidyl peptidase IV, DPP-IV) can effectively and to degrade rapidly glucagon-like peptide 1 (GLP-1), GLP-1 is one of insulin production and the most effective stimulant of secretion, therefore suppress DPP-IV can strengthen the effect of endogenous GLP-1, thus improve the level of Regular Insulin in blood.Current medical science has confirmed that DPP-IV inhibitor is a kind of novel antidiabetic treatment medicine, has had multiple medicine list marketing at present.Clinical effectiveness shows such medicine and has good hypoglycemic effect, does not find the untoward reaction thing such as the common body weight increase that other diabetes medicaments produce and hypoglycemia simultaneously.
The major structural types of existing DPP-IV inhibitor has: chemically structure type divides and is mainly divided into piperazine and triazole species, 2-cyano-pyrolidin class, thiazolidines, Pyrimdinone, and other types structure medicament.
The invention discloses a diamond-like alkanamine tetrazole DPP-IV inhibitor, these compounds may be used for the medicine preparing treatment diabetes.
Summary of the invention
An object of the present invention is to provide one and there is excellent activity, there is compound and the pharmacy acceptable salt thereof of general formula I.
Another object of the present invention is to provide preparation and has the compound of general formula I and the method for salt thereof.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula I has following structural formula:
Wherein, R
1be selected from halogenic substituent.
Further, preferred following compound:
Compound of Formula I of the present invention is synthesized by following steps:
Compound II per and bromoacetyl bromide III are obtained by reacting compound IV in the presence of a base, and the latter and 2H-tetrazole-5-formic acid V are obtained by reacting compound VI in the presence of a base, compound VI with react with VII under condensing agent exists, obtain Compound I; Above-mentioned condensing agent comprises N, N'-dicyclohexyl carbodiimide (DCC), N-ethyl-N'-(3-dimethylamino-propyl) carbodiimide hydrochloride (EDC) and carbonyl dimidazoles (CDI) etc., these condensing agents can with organic bases conbined usage, as triethylamine, diisopropyl ethyl amine (DIPEA) and DMAP (DMAP) etc.Wherein, R
1definition as previously mentioned.
The pharmacy acceptable salt of formula I of the present invention comprises, but be not limited to and various mineral acid, such as, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid etc., or organic acid, the pharmacy acceptable salt that such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, toxilic acid, amino acid etc. generate.
Compound or its salt shown in formula I has the restraining effect of DPP-IV, can be used as effective constituent for the preparation of in treatment diabetes medicament; Preferably, described diabetes are non insulin dependent diabetes.The activity of the compounds of this invention is verified by the external restraining effect to DPP-IV enzyme.
Compound of Formula I of the present invention or its salt have the restraining effect of DPP-IV, can be used as the medicine of effective constituent for the preparation of diabetes aspect.The activity of compound of Formula I of the present invention is by hypoglycemic modelling verification in body.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.These situations comprise: the physical state of patient, route of administration, age, body weight, individual reaction to medicine, the severity etc. of symptom.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
Embodiment 1
2.30g (10mmol) Compound II per-1 and 3.04g (30mmol) triethylamine are dissolved in the methylene dichloride of 20mL drying, ice-water bath cooling is lower stirs, and then slowly drips 2.42g (12mmol) compound III and is dissolved in the solution made in the methylene dichloride of 5mL drying.After dropwising, reaction mixture at room temperature continues stirring 1 hour.Reaction mixture is poured in 200mL frozen water, stir, with 50mL × 3 dichloromethane extraction, merge extraction phase brine It, anhydrous sodium sulfate drying, then evaporate to dryness on a rotary evaporator, the resistates column chromatography purification obtained, obtains the sterling of IV-1, white solid, ESI-MS, m/z=350 ([M+H]
+).
2.11g (6mmol) compound IV-1,0.68g (6mmol) compound V, 1.00g (6mmol) solid potassiumiodide and 4.15g (30mmol) solid carbonic acid potassium 120 DEG C of stirred under nitrogen in the DMF of 20mL drying spend the night.Be poured into after reaction mixture is slightly cold in 200mL frozen water, stir, with 50mL × 3 dichloromethane extraction, merge extraction phase brine It, anhydrous sodium sulfate drying, then evaporate to dryness on a rotary evaporator, the resistates column chromatography purification obtained, obtains the sterling of VI-1, white solid, ESI-MS, m/z=383,385 ([M+H]
+).
1.15g (3mmol) compound VI-1,0.29g (mmol) compound VI I and 0.62g (3mmol) DCC room temperature for overnight in the THF of 6mL drying.Solid in suction filtration removing reaction mixture, filtrate is evaporate to dryness on a rotary evaporator, and resistates column chromatography purification obtains the sterling of product I-1, white solid, ESI-MS, m/z=463,461 ([M+H]
+).
Embodiment 2-5
Use the method identical with embodiment 1, can following compounds be prepared.
Embodiment 5 compound measures the restraining effect of DPP-IV enzyme
Use the fluorescence DPP4 activity detection kit of BPS Biological Science Co., Ltd, measure the inhibit activities of compound of the present invention to DPP-IV enzyme.
Be respectively by gradient dilution concentration successively by sample: 5,10,30,100 and 200ng/kg, fluorescent reaction 96 orifice plate, according to the form below adds sample:
22 DEG C of water-baths, place 10min, Spectra Max M5 type fluorimetric detector exciting light 350nm, with 450nm fluorometric assay absorption value.IC is calculated according to concentration-fluorescence intensity curves
50value, the results are shown in following table:
Compound is to the IC of the suppression of DPP-IV enzyme
50value
As can be seen from the above table, compound of the present invention has very strong restraining effect to DPP-IV enzyme.
Claims (4)
1. there is compound or its pharmacy acceptable salt of general formula I:
Wherein, R
1be selected from halogenic substituent.
2. the compound of Formula I that defines of claim 1 or its pharmacy acceptable salt, is selected from:
3. synthesize the method for the compound of Formula I that defines of claim 1-2 or its pharmacy acceptable salt, comprise the following steps:
Compound II per and bromoacetyl bromide III are obtained by reacting compound IV in the presence of a base, and the latter and 2H-tetrazole-5-formic acid V are obtained by reacting compound VI in the presence of a base, compound VI with react with VII under condensing agent exists, obtain Compound I, wherein R
1corresponding to described in any one of claim 1-2.
4. the compound of Formula I that defines of claim 1-2 or the application of its pharmacy acceptable salt in preparation treatment diabetes medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510016493.2A CN104530009B (en) | 2015-01-13 | 2015-01-13 | Amantadine tetrazole derivant, Preparation Method And The Use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510016493.2A CN104530009B (en) | 2015-01-13 | 2015-01-13 | Amantadine tetrazole derivant, Preparation Method And The Use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104530009A true CN104530009A (en) | 2015-04-22 |
| CN104530009B CN104530009B (en) | 2016-08-24 |
Family
ID=52845680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510016493.2A Active CN104530009B (en) | 2015-01-13 | 2015-01-13 | Amantadine tetrazole derivant, Preparation Method And The Use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104530009B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111423396A (en) * | 2020-04-30 | 2020-07-17 | 沈阳药科大学 | sEH inhibitor, and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012441A1 (en) * | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
| CN1921856A (en) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| CN101318922A (en) * | 2007-06-08 | 2008-12-10 | 上海阳帆医药科技有限公司 | Novel dipeptidyl peptidase restrainer, synthesizing process and uses thereof |
| CN101448785A (en) * | 2006-04-03 | 2009-06-03 | 矩阵实验室有限公司 | Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them |
| EP2318007B1 (en) * | 2008-08-15 | 2013-01-23 | N30 Pharmaceuticals, Inc. | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
-
2015
- 2015-01-13 CN CN201510016493.2A patent/CN104530009B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1921856A (en) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| WO2006012441A1 (en) * | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
| CN101448785A (en) * | 2006-04-03 | 2009-06-03 | 矩阵实验室有限公司 | Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them |
| CN101318922A (en) * | 2007-06-08 | 2008-12-10 | 上海阳帆医药科技有限公司 | Novel dipeptidyl peptidase restrainer, synthesizing process and uses thereof |
| EP2318007B1 (en) * | 2008-08-15 | 2013-01-23 | N30 Pharmaceuticals, Inc. | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111423396A (en) * | 2020-04-30 | 2020-07-17 | 沈阳药科大学 | sEH inhibitor, and preparation method and application thereof |
| CN111423396B (en) * | 2020-04-30 | 2023-01-06 | 沈阳药科大学 | sEH inhibitor, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104530009B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104530010B (en) | A kind of hydroxyadamantane tetrazotized zole compound, Preparation Method And The Use | |
| CN104530012B (en) | Amantadine tetrazole derivative, Preparation Method And The Use | |
| CN104530009A (en) | Amantadine tetrazolium derivative, and preparing method and application thereof | |
| CN104530011B (en) | A kind of itrile group diamantane tetrazotized zole compound, Preparation Method And The Use | |
| CN104496968A (en) | Compound with halogen-substituted adamantane tetrazole structure and preparation method and application thereof | |
| CN104478860B (en) | Diamantane (obsolete) tetrazole derivant, Preparation Method And The Use | |
| CN104447704B (en) | A kind of itrile group diamantane (obsolete) tetrazotized zole compound, Preparation Method And The Use | |
| CN104478859B (en) | A kind of hydroxyadamantane tetrazotized zole compound, Preparation Method And The Use | |
| CN104478861A (en) | Nitro adamantane-tetrazole compound, preparing method of nitro adamantane-tetrazole compound and application of nitro adamantane-tetrazole compound | |
| CN104529857B (en) | Halo diamantane amide derivatives, Preparation Method And The Use | |
| CN104447703B (en) | A kind of nitro diamantane (obsolete) tetrazotized zole compound, Preparation Method And The Use | |
| CN104447479B (en) | Containing diamantane and amide derivatives, Preparation Method And The Use | |
| CN104478778B (en) | Diamantane amide derivatives, Preparation Method And The Use | |
| CN104529855B (en) | Derivative, the Preparation Method And The Use of a kind of hydroxyl diamantane and amide structure | |
| CN104447478B (en) | Derivative, the Preparation Method And The Use of a kind of nitrile group-containing diamantane and amide structure | |
| CN104496877B (en) | A kind of itrile group diamantane amide derivatives, Preparation Method And The Use | |
| CN104356046B (en) | Cyclohexane-carboxylic acid amide derivatives that cycloalkyl replaces and application thereof | |
| CN104529858A (en) | Derivative with halogeneated and amides and preparation method and application thereof | |
| CN104478777B (en) | A kind of containing nitro diamantane (obsolete) with the derivant of amide structure, Preparation Method And The Use | |
| CN104447500A (en) | Halogen-substituted benzamidocyclohexanecarboxylic acid derivatives and applications thereof | |
| CN104356048B (en) | Cyclohexane-carboxylic acid amide derivatives, Preparation Method And The Use | |
| CN104447501A (en) | Alkyl-substituted benzamidocyclohexanecarboxylic acid derivatives and applications thereof | |
| CN104356047A (en) | Substituted cyclohexane carboxylic acid amide derivative and pharmaceutical application thereof | |
| CN104496876A (en) | Hydroxyl diamantane amide derivative, preparation method and use thereof | |
| CN104529856A (en) | Nitro adamantine amide derivative and preparing method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Amantadine tetrazolium derivative, and preparing method and application thereof Effective date of registration: 20170816 Granted publication date: 20160824 Pledgee: Guangdong Nanhai Rural Commercial Bank branch branch of Limited by Share Ltd Pledgor: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY CO., LTD. Registration number: 2017990000756 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190604 Granted publication date: 20160824 Pledgee: Guangdong Nanhai Rural Commercial Bank branch branch of Limited by Share Ltd Pledgor: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY CO., LTD. Registration number: 2017990000756 |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190912 Address after: 064200 West of South Road of East Second Ring Road and South of Jianchang Street, Zunhua City, Tangshan City, Hebei Province Patentee after: Hebei Haohui Crushing Machinery Equipment Co., Ltd. Address before: Chancheng district has 528000 Taiwan public in Guangdong province Foshan City No. 32 first floor 1636, shop No. 1637 Patentee before: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201014 Address after: 064200 Huaming Jiayuan Commercial and Residential Building H7, West of Huaming South Road, Zunhua City, Tangshan City, Hebei Province Patentee after: Tangshan Chuangke Jinfu Technology Co.,Ltd. Address before: 064200 West of South Road of East Second Ring Road and South of Jianchang Street, Zunhua City, Tangshan City, Hebei Province Patentee before: Hebei Haohui Crushing Machinery Equipment Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201229 Address after: No.66 Industrial Park, suyangshan Town, Pizhou City, Xuzhou City, Jiangsu Province Patentee after: XUZHOU HENGHUA PACKAGING TECHNOLOGY Co.,Ltd. Address before: 064200 commercial building H7, Huaming Jiayuan commercial and residential building, west of Huaming South Road, Zunhua City, Tangshan City, Hebei Province Patentee before: Tangshan Chuangke Jinfu Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |